Felix Early Thai FDA Approval, Commercial Launch Accelerates
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Memphasys Ltd has announced that its Felix™ System has received early approval from the Thai Food and Drug Administration, allowing for commercial sales in Thailand sooner than expected. This approval activates a three-year exclusive distribution agreement with IVF Envimed Co., Ltd., which includes a minimum purchase commitment. The company reports strong initial interest from IVF clinics, leading to additional orders for Felix™ cartridges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Memphasys
- Felix Registration Achieved in Vietnam and Cartridge Order
- European Commercial Roll-out continues with Poland Agreement
- Exclusive Thailand Commercialisation Agreement Secured
- UK Market Entry & Acceleration of Commercial Expansion
- Successful $1.2M Placement and Convertible Note Extended
Later from Memphasys
- EUR526,500 Nordic Agreement Expands Felix European Footprint
- Felix Registration Achieved in Turkey, Sales Commence
- Memphasys Secures European Felix Agreement
- Potential Expedited FDA Pathway to US IVF Market
- Memphasys receives A$3.5 million from Peters Investments
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys